Recent advancements in disease management and historical health policy investigations highlight a broad spectrum of medical developments.

The FDA has approved Eli Lilly's Mounjaro (tirzepatide) for reducing cardiovascular risks specifically in adults diagnosed with type 2 diabetes.

A new study indicates that patients with atrial fibrillation at intermediate stroke risk benefit from anticoagulation therapy with DOACs, showing fewer clinical events without increased major bleeding.

Research among adult veterans demonstrates that initiating oseltamivir treatment within six hours of an influenza diagnosis significantly lowers hospitalization risks.

Pediatric studies reinforce that administering antiviral treatments within 48 hours of symptom onset effectively reduces hospitalization risks for children with the flu.

Clinical trials for the cancer drug Ibrutinib show it fails to improve overall survival in high-risk early-stage chronic lymphocytic leukemia, despite some benefits in event-free survival for specific genetic subgroups.

New findings reveal a correlation between type 2 diabetes in older adults and accelerated cortical thinning in the brain, alongside a more rapid decline in processing speed.

Vitamin B3 supplementation has shown potential in improving nailfold capillary patterns and quality of life for patients diagnosed with primary Raynaud phenomenon.

An expert investigation into Greenland's historical forced contraception campaign concluded that while the actions violated women's fundamental human rights, they did not meet the legal criteria for genocide.